Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. 2002

Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
Laboratoire de Chimie Bioorganique, UMR 6001 CNRS, Université de Nice Sophia-Antipolis, Faculté des Sciences, Parc Valrose, 06108 Nice Cedex 2, France.

OBJECTIVE [corrected] This study is dedicated to the permeation of various amino acid-, D-glucose-, and PEG-conjugates of indinavir, saquinavir, and nelfinavir across monolayers of Caco-2 cells as models of the intestinal barrier. This screening is aimed at detecting the most promising prodrugs for improving the intestinal absorption of these protease inhibitors. METHODS The bidirectional transport of the prodrugs was investigated using P-gp-expressing Caco-2 monolayers grown on membrane inserts using high-performance liquid chromatography for quantitation. RESULTS The L-valyl, L-leucyl, and L-phenylalanyl ester conjugates led to an enhancement of the absorptive flux of indinavir or saquinavir. These results are likely attributable to an active transport mechanism and/or to a decrease of their efflux by carriers such as P-gp. Connection of tyrosine through its hydroxyl, of D-glucose, or of polyethylene glycol decreased their absorptive and secretory diffusion. CONCLUSIONS Conjugation of the protease inhibitors to amino acids constitutes a most appealing alternative that could improve their intestinal absorption and oral bioavailability. Whether it could improve their delivery into the central nervous system remains to be explored. D-Glucose conjugation will most probably not improve their intestinal absorption or their crossing of the blood-brain barrier. If some pharmacologic benefits are to be expected from PEG-protease inhibitor conjugates, they must then be administered intravenously.

UI MeSH Term Description Entries
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D004847 Epithelial Cells Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells. Adenomatous Epithelial Cells,Columnar Glandular Epithelial Cells,Cuboidal Glandular Epithelial Cells,Glandular Epithelial Cells,Squamous Cells,Squamous Epithelial Cells,Transitional Epithelial Cells,Adenomatous Epithelial Cell,Cell, Adenomatous Epithelial,Cell, Epithelial,Cell, Glandular Epithelial,Cell, Squamous,Cell, Squamous Epithelial,Cell, Transitional Epithelial,Cells, Adenomatous Epithelial,Cells, Epithelial,Cells, Glandular Epithelial,Cells, Squamous,Cells, Squamous Epithelial,Cells, Transitional Epithelial,Epithelial Cell,Epithelial Cell, Adenomatous,Epithelial Cell, Glandular,Epithelial Cell, Squamous,Epithelial Cell, Transitional,Epithelial Cells, Adenomatous,Epithelial Cells, Glandular,Epithelial Cells, Squamous,Epithelial Cells, Transitional,Glandular Epithelial Cell,Squamous Cell,Squamous Epithelial Cell,Transitional Epithelial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D018938 Caco-2 Cells Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells, such as ENTEROCYTES. These cells are valuable in vitro tools for studies related to intestinal cell function and differentiation. Caco 2 Cells,Caco-2 Cell,Cell, Caco-2,Cells, Caco-2
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir
D019888 Nelfinavir A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. AG 1343,AG-1343,AG1343,Nelfinavir Mesylate,Nelfinavir Monomethane Sulfonate,Viracept,Mesylate, Nelfinavir,Monomethane Sulfonate, Nelfinavir,Sulfonate, Nelfinavir Monomethane

Related Publications

Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
January 2009, European journal of drug metabolism and pharmacokinetics,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
June 2002, Journal of controlled release : official journal of the Controlled Release Society,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
May 2013, Food chemistry,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
March 1998, Pharmaceutical research,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
September 2009, General physiology and biophysics,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
March 2005, The Journal of membrane biology,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
June 2007, Journal of agricultural and food chemistry,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
January 1996, Metal-based drugs,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
May 2000, Pharmaceutical research,
Marielle Rouquayrol, and Bérangère Gaucher, and Dominique Roche, and Jacques Greiner, and Pierre Vierling
April 2001, World journal of gastroenterology,
Copied contents to your clipboard!